TY - JOUR
T1 - Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models
AU - Liu, Xia
AU - Taftaf, Rokana
AU - Kawaguchi, Madoka
AU - Chang, Ya Fang
AU - Chen, Wenjing
AU - Entenberg, David
AU - Zhang, Youbin
AU - Gerratana, Lorenzo
AU - Huang, Simo
AU - Patel, Dhwani B.
AU - Tsui, Elizabeth
AU - Adorno-Cruz, Valery
AU - Chirieleison, Steven M.
AU - Cao, Yue
AU - Harney, Allison S.
AU - Patel, Shivani
AU - Patsialou, Antonia
AU - Shen, Yang
AU - Avril, Stefanie
AU - Gilmore, Hannah L.
AU - Lathia, Justin D.
AU - Abbott, Derek W.
AU - Cristofanilli, Massimo
AU - Condeelis, John S.
AU - Liu, Huiping
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/1
Y1 - 2019/1
N2 - Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less frequently detected but more metastatic than single CTCs of patients with triple-negative breast cancer and representative patient-derived xenograft models. Using intravital multiphoton microscopic imaging, we found that clustered tumor cells in migration and circulation resulted from aggregation of individual tumor cells rather than collective migration and cohesive shedding. Aggregated tumor cells exhibited enriched expression of the breast cancer stem cell marker CD44 and promoted tumorigenesis and polyclonal metastasis. Depletion of CD44 effectively prevented tumor cell aggregation and decreased PAK2 levels. The intercellular CD44–CD44 homophilic interactions directed multicellular aggregation, requiring its N-terminal domain, and initiated CD44–PAK2 interactions for further activation of FAK signaling. Our studies highlight that CD44 + CTC clusters, whose presence is correlated with a poor prognosis of patients with breast cancer, can serve as novel therapeutic targets of polyclonal metastasis. SIGNIFICANCE: CTCs not only serve as important biomarkers for liquid biopsies, but also mediate devastating metastases. CD44 homophilic interactions and subsequent CD44–PAK2 interactions mediate tumor cluster aggregation. This will lead to innovative biomarker applications to predict prognosis, facilitate development of new targeting strategies to block polyclonal metastasis, and improve clinical outcomes.
AB - Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less frequently detected but more metastatic than single CTCs of patients with triple-negative breast cancer and representative patient-derived xenograft models. Using intravital multiphoton microscopic imaging, we found that clustered tumor cells in migration and circulation resulted from aggregation of individual tumor cells rather than collective migration and cohesive shedding. Aggregated tumor cells exhibited enriched expression of the breast cancer stem cell marker CD44 and promoted tumorigenesis and polyclonal metastasis. Depletion of CD44 effectively prevented tumor cell aggregation and decreased PAK2 levels. The intercellular CD44–CD44 homophilic interactions directed multicellular aggregation, requiring its N-terminal domain, and initiated CD44–PAK2 interactions for further activation of FAK signaling. Our studies highlight that CD44 + CTC clusters, whose presence is correlated with a poor prognosis of patients with breast cancer, can serve as novel therapeutic targets of polyclonal metastasis. SIGNIFICANCE: CTCs not only serve as important biomarkers for liquid biopsies, but also mediate devastating metastases. CD44 homophilic interactions and subsequent CD44–PAK2 interactions mediate tumor cluster aggregation. This will lead to innovative biomarker applications to predict prognosis, facilitate development of new targeting strategies to block polyclonal metastasis, and improve clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85057632452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057632452&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-18-0065
DO - 10.1158/2159-8290.CD-18-0065
M3 - Article
C2 - 30361447
AN - SCOPUS:85057632452
SN - 2159-8274
VL - 9
SP - 96
EP - 113
JO - Cancer Discovery
JF - Cancer Discovery
IS - 1
ER -